Catalyst Capital Advisors LLC Has $2.53 Million Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Catalyst Capital Advisors LLC grew its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 7.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 178,000 shares of the company’s stock after acquiring an additional 12,000 shares during the quarter. Catalyst Capital Advisors LLC’s holdings in Takeda Pharmaceutical were worth $2,531,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of TAK. Allspring Global Investments Holdings LLC bought a new stake in shares of Takeda Pharmaceutical during the first quarter worth about $108,000. Sequoia Financial Advisors LLC grew its holdings in shares of Takeda Pharmaceutical by 10.7% during the first quarter. Sequoia Financial Advisors LLC now owns 22,396 shares of the company’s stock worth $311,000 after purchasing an additional 2,159 shares during the last quarter. Callan Capital LLC grew its holdings in shares of Takeda Pharmaceutical by 89.3% during the first quarter. Callan Capital LLC now owns 25,461 shares of the company’s stock worth $354,000 after purchasing an additional 12,010 shares during the last quarter. Lester Murray Antman dba SimplyRich bought a new stake in shares of Takeda Pharmaceutical during the first quarter worth about $351,000. Finally, Gallacher Capital Management LLC grew its holdings in shares of Takeda Pharmaceutical by 6.1% during the first quarter. Gallacher Capital Management LLC now owns 16,229 shares of the company’s stock worth $225,000 after purchasing an additional 927 shares during the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

NYSE:TAK opened at $14.05 on Tuesday. The stock has a market cap of $44.71 billion, a P/E ratio of 24.22, a price-to-earnings-growth ratio of 0.27 and a beta of 0.54. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64. The stock’s 50-day moving average is $14.46 and its 200-day moving average is $13.80. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.08.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.